ImCheck Therapeutics
Created in 2015
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
552 9,229Global tags
Activities
Technologies
Entity types
Location
31 Chemin Joseph Aiguier, CS 70071 13402, MARSEILLE Cedex 20, 13009 Marseille, France
Marseille
France
Employees
Scale: 11-50
Estimated: 56
SIREN
812428142Engaged corporates
32
15 22Added in Motherbase
4 years ago
biotech Value proposition
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
antibodies, immuno-oncology, Immune checkpoint Modulators, Auto-immunity, innate immunity, oncology, cancer, precision-based medicine, adaptative immunity, EVICTIONtrial, ICT01, and gamma-deltaTcellsOriginal language
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.
As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class” activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImCheck’s antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases.
Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in γδ T cells and butyrophilins research; from the experience of an expert management team; and from the commitment of leading US and European investors.
Imchecktherapeutics.com: Imcheck Therapeutics
Imcheck Therapeutics : Opening new spaces in Immuno-Oncology.
https://imchecktherapeutics.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Other 7 Feb 2018 | | |
 Kurma Partners Startup accelerator & VC, Venture Capital and Private Equity Principals | Kurma Partners Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 26 May 2024 | | |
 Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 23 Oct 2024 | | |
 AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | AstraZeneca Pharmaceutical, Pharmaceutical Manufacturing | Other 6 Feb 2020 | | |
 Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Other 23 Sep 2023 | | |
 Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Other 23 Sep 2023 | | |
 MSD Pharmaceutical, Pharmaceutical Manufacturing | MSD Pharmaceutical, Pharmaceutical Manufacturing | Other 17 Apr 2018 | | |
 SATT Sud-Est Research, National and local authorities, Research Services | SATT Sud-Est Research, National and local authorities, Research Services | Other 23 Oct 2024 | | |
 Le Journal des Entreprises Media, Newspaper Publishing | Le Journal des Entreprises Media, Newspaper Publishing | Other 3 Apr 2023 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 17 Jun 2020 23 Oct 2024 | | |